Development and characterization of 99mTc-timolol maleate for evaluating efficacy of in situ ocular drug delivery system

AAPS PharmSciTech

Volumn 10, Issue 2, 2009, Pages 540-546

  Gupta, Himanshu ^a,b   Aqil, M ^a   Khar, R K ^a   Ali, Asgar ^a   Bhatnagar, Aseem ^b   Mittal, Gaurav ^b   Jain, Sanyog ^b,c  

^a HAMDARD UNIVERSITY   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^c NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

99mTc; Chitosan; Gamma scintigraphy; In situ gel; Radio labeling; Timolol maleate

Indexed keywords

CHITOSAN; HYDROXYPROPYLMETHYLCELLULOSE; PLACEBO; TECHNETIUM 99M; TIMOLOL MALEATE; DIAGNOSTIC AGENT; TECHNETIUM; TIMOLOL;

ARTICLE; BLADDER; CHORIOALLANTOIS; CONTROLLED STUDY; CORNEA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG STABILITY; GAMMA SCINTIGRAPHY; IN VITRO STUDY; ISOTOPE LABELING; KIDNEY; PROCESS OPTIMIZATION; ANIMAL; FEMALE; MALE; METABOLISM; PH; RABBIT; SOLUBILITY;

ANIMALS; CORNEA; DRUG DELIVERY SYSTEMS; FEMALE; HYDROGEN-ION CONCENTRATION; ISOTOPE LABELING; MALE; RABBITS; SOLUBILITY; TECHNETIUM; TIMOLOL;

EID: 67549123418     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9238-x     Document Type: Article

References (16)

1. Maurice DM. Kinetics of topically applied drugs. In: Saettone MS, Bucci P, Padova S, editors. Ophthalmic drug delivery: Biopharmaceutical, technological and clinical aspects. Fidia research series. vol 11. Padova: Liviana; 1987. p. 19-26.
2. Schoenwald RD. Ocular drug delivery: Pharmacokinetic considerations. Clin Pharmacokinet 1990;18:255-69.
3. Middleton DL, Leung SS, Robinson JR. In: Lenaerts V, Gurny R, editors. Bioadhesive drug delivery systems. Boca Raton: CRC; 1990. p. 179-202.
4. Swarbrick J, Boylan J. Ocular drug formulation and delivery. In encyclopedia of pharmaceutical technology. New York: Marcel Dekker; 1995. p. 43-75.
5. Ranade VV, Hollinger MA. Intranasal and ocular drug delivery. In Drug delivery systems. Boca Raton: CRC; 1996. p. 209-38.
6. Felt O, Baeyens V. Mucosal drug delivery: Ocular. Encyclopedia of controlled drug delivery, vol II. Hoboken: Wiley; 1999. p. 605-26.
7. Chiou GCY, Watanabe K. Drug delivery to the eyes. In: Ihler GM, editor. Methods of drug delivery: International encyclopedia of pharmacology and therapeutics. London: Pergamon; 1986. p. 203-10.
8. Nanjawade BK, Manvi FV, Manjappa AS. In situ -forming hydrogels for sustained ophthalmic drug delivery. J Control Rel 2007;122:119-34.
9. Gupta H, Jain S, Mathur R, Mishra P, Mishra AK, Velpandian T. Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv 2007;14(8):507-15.
10. Davis SS, Hardy JG, Newman SP, Wilding IR. Gamma scintigraphy in the evaluation of pharmaceutical dosage forms. Eur J Nucl Med 1992;19(11):971-86.
11. Balasubramaniam J, Kant S, Pandit JK. In vitro and in vivo evaluation of the Gelrite® gellan gum-based ocular delivery system for indomethacin. Acta Pharm 2003;53:251-61.
12. Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Rel 2001;73:205-11.
13. Lin H, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Rel 2000;69(3):379-88.
14. Higashiyama M, Inada K, Ohtori A, Tojo K. Improvement of the ocular bioavailability of timolol by sorbic acid. Int J Pharm 2004;272(1-2):91-8.
15. Velpandian T, Bankoti R, Humayun S, Ravi AK, Kumari SS, Biswas NR. Comparative evaluation of possible ocular photochemical toxicity of fluoroquinolones meant for ocular use in experimental models. Ind J Exp Biol 2006;5:387.
16. Spielmann H. Ocular irritation. In: Castle JV, Gomez MJ, editors. In Vitro methods in pharmaceutical research. San Diego: Academic; 1997. p. 265-87.